<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718468</url>
  </required_header>
  <id_info>
    <org_study_id>CT-QV-31</org_study_id>
    <nct_id>NCT03718468</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine</brief_title>
  <official_title>A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled&#xD;
      Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the active&#xD;
      control, Fluarix Tetra. This study is designed to be a randomized, open-labelled,&#xD;
      active-controlled, parallel, phase III study recruiting subjects from multiple study sites.&#xD;
&#xD;
      Approximately 840 eligible subjects are planned to enroll in order to obtain 800 evaluable (=&#xD;
      per-protocol) subjects. Subjects will be randomized and assigned to GC FLU or Fluarix Tetra&#xD;
      (active control, AC) group in 1:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Geometric Mean Titer (GMT) Ratio</measure>
    <time_frame>21 days after the vaccination</time_frame>
    <description>The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Seroconversion Rate</measure>
    <time_frame>21 days after the vaccination</time_frame>
    <description>The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">842</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GC Flu Quadrivalent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix tetra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC FLU Quadrivalent</intervention_name>
    <description>A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.</description>
    <arm_group_label>GC Flu Quadrivalent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix Tetra</intervention_name>
    <description>A single dose administration of Fluarix Tetra will be through intramuscular injection.</description>
    <arm_group_label>Fluarix tetra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Either gender, aged 20 to 50 years old (inclusive)&#xD;
&#xD;
          3. Willing and able to comply with all the required study visits and follow-up defined by&#xD;
             this protocol&#xD;
&#xD;
          4. Female subject with childbearing potential or male subject with female spouse/partner&#xD;
             with childbearing potential must agree to use highly effective contraceptives from 15&#xD;
             days prior to vaccination until 60 days after vaccination. At least two forms of birth&#xD;
             control must be adopted and one of which must be a barrier method. Acceptable forms&#xD;
             include:&#xD;
&#xD;
               -  Established use of oral, injected or implanted hormonal methods of contraception&#xD;
&#xD;
               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               -  Barrier methods of contraception: condom, or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With previous known or potential exposure to influenza virus within 12 weeks prior to&#xD;
             vaccination&#xD;
&#xD;
          2. Received seasonal influenza vaccine (registered or investigational) within 24 weeks&#xD;
             prior to vaccination&#xD;
&#xD;
          3. Received any vaccine other than seasonal influenza vaccine within 6 weeks prior to&#xD;
             vaccination&#xD;
&#xD;
          4. Received other investigational products (including medications and vaccines) within 6&#xD;
             weeks prior to vaccination&#xD;
&#xD;
          5. Administered immunoglobulins and/or other blood products within the 12 weeks prior to&#xD;
             vaccination&#xD;
&#xD;
          6. Known or suspected hypersensitivity to any component of vaccines (including egg&#xD;
             proteins); or history of allergy to consumption of eggs&#xD;
&#xD;
          7. History of inflammatory or degenerative neurological disease (e.g., Guillain-Barre&#xD;
             syndrome)&#xD;
&#xD;
          8. With confirmed or suspected immunosuppressive or immunodeficient condition (e.g. HIV&#xD;
             infection), or received &gt; 14 days of systemic steroid with equivalent dosage equal or&#xD;
             over to 0.5 mg/kg/day prednisolone or other immune-modifying agents within 24 weeks&#xD;
             prior to vaccination&#xD;
&#xD;
          9. Positive in HIV, HBsAg, or HCV test&#xD;
&#xD;
         10. With fever (defined as body temperature equal or over to 38 Â°C by any method) on the&#xD;
             day of vaccination&#xD;
&#xD;
         11. With ongoing acute diseases or within the past 2 years serious medical conditions&#xD;
             (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association&#xD;
             grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g.&#xD;
             alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality&#xD;
             that in the investigators' opinion could interfere with the results of the trial or&#xD;
             adversely affect the safety of the subject&#xD;
&#xD;
         12. Female subject who is lactating or has positive serum or urine pregnancy test at&#xD;
             screening or vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szu-Min Hsieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Municipal Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

